FDA
-
-
-
-
-
-
-
Creative Medical reports 93% response rate in knee osteoarthritis study
-
-
-
-
-
-
-
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
-
-
-
-
-
-
-
Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential
-
-
-
-
-
-
-
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
-
-
-
-
-
-
-
Creative Medical Technology (CELZ) Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
-
-
-
-
-
-
-
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain
-
-
-
-
-
-
-
Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update
-
328,460 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

